Zai Lab Ltd.

Zai Lab Ltd. is a biopharmaceutical company, which engages in the developing and commercializing therapies that address medical conditions with unmet needs in oncology, autoimmune disorders, infectious diseases, and neuroscience. Its products include Zejula, Optune, Qinlock, and Nuzyra. The company was founded by Samantha Ying Du and Marietta Wu in April 2014 and is headquartered in Shanghai, China.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

SHANGHAI, SAN FRANCISCO and CAMBRIDGE, Mass., Oct. 26, 2021 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), a patient-focused, innovative, commercial-stage, global biopharmaceutical company, today announced that it will report financial results and corporate updates for the third quarter ended September 30, 2021 after the closing of the U.S. equity markets on November 9, 2021. The Company will host a live conference call and webcast on November 10, 2021, at 8:00 a.m. ET.

Zai Lab to Announce Third Quarter 2021 Financial Results

Zai Lab expects to enroll Chinese patients across several disease-specific B-cell non-Hodgkin lymphoma (B-NHL) cohorts in the potentially pivotal, global Phase 2 study of odronextamab monotherapy Zai Lab expects to enroll Chinese patients across several disease-specific B-cell non-Hodgkin lymphoma (B-NHL) cohorts in the potentially pivotal, global Phase 2 study of odronextamab monotherapy

Zai Lab Announces First Patient Treated in Greater China Portion of Potentially Registrational, Global Phase 2 Study of Odronextamab

Zai Lab Limited (NASDAQ: ZLAB) announced topline results from Phase 1b study of a topical formulation of ZL-1102 in adults with mild-to-moderate chronic plaque psoriasis (CPP). ZL-1102 is an investigational, novel human VH antibody fragment targeting the IL-17A cytokine.

Zai Lab Posts Encouraging Data From Early-Stage Plaque Psoriasis Trial

CAMBRIDGE, England--(BUSINESS WIRE)--Crescendo Biologics Ltd (Crescendo), a clinical stage immuno-oncology company developing novel, targeted T cell enhancing therapeutics, today announces that Zai Lab (NASDAQ: ZLAB; HKEX: 9688) has reported positive topline results from a randomized, double-blind, placebo-controlled Phase 1b proof-of-concept study of ZL-1102, an anti-IL-17A targeting Humabody®. The Phase 1b trial was a first-in-human study to evaluate the safety, pharmacokinetics and efficacy

Crescendo Biologics Announces That Zai Lab Has Achieved Proof-of-Concept for ZL-1102 (Humabody®, CB001) in a Phase 1b Clinical Trial in Psoriasis Patients

Topical therapy with ZL-1102 resulted in clinical improvement in local PASI score, erythema and scaling, target lesion size, and responder rates in patients with mild-to-moderate chronic plaque psoriasis; consistent improvement was seen over time

ZL-1102, Zai Lab's Internally Developed Novel Human VH Antibody Fragment, Achieved Proof of Concept in Phase 1b Psoriasis Study

SHANGHAI, SAN FRANCISCO, and CAMBRIDGE, Mass., Oct. 18, 2021 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), a patient-focused, innovative, commercial-stage, global biopharmaceutical company, today announced that it has appointed Scott Morrison to its Board of Directors. Mr. Morrison will also serve as a member of the Audit Committee.

Zai Lab Appoints Scott Morrison to its Board of Directors

SHANGHAI and SAN FRANCISCO, Oct. 11, 2021 (GLOBE NEWSWIRE) -- Zai Lab Limited (“Zai Lab”) (NASDAQ: ZLAB; HKEX: 9688), an innovative commercial-stage biopharmaceutical company, today announced that management from Zai Lab will be presenting at the following upcoming virtual investor conferences in October:

Zai Lab Announces Upcoming Presentations in October Investor Conferences

-- Demonstrated efficacy and safety consistent with global SOPHIA study-- Company expects to file BLA in China in advanced HER2+ breast cancer by approximately year end 2021

Zai Lab Announces Margetuximab Achieved Primary Objective in Bridging Study in Advanced HER2+ Breast Cancer in Greater China

SHANGHAI, China and SAN FRANCISCO, Oct. 04, 2021 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) partner Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced the U.S. Food and Drug Administration (FDA) granted a seventh regulatory designation to lead drug candidate, repotrectinib.

Zai Lab Partner Turning Point Therapeutics Granted Breakthrough Therapy Designation for Repotrectinib Treatment in Patients With NTRK-Positive, TKI-Pretreated Advanced Solid Tumors

Final data collection is expected in the first half of 2022

Zai Lab and Novocure Announce Last Patient Enrolled in Phase 2 Pilot Trial of Tumor Treating Fields Plus Chemotherapy as First-Line Treatment in Gastric Cancer in China

Novocure

ST. HELIER, Jersey & SHANGHAI--(BUSINESS WIRE)-- #GastricCancer--Novocure and Zai Lab announced that the last patient has been enrolled in a phase 2 pilot trial of TTFields plus chemotherapy in gastric cancer.

Novocure and Zai Lab Announce Last Patient Enrolled in Phase 2 Pilot Trial of Tumor Treating Fields Plus Chemotherapy as First-Line Treatment in Gastric Cancer in China

-- Expects to have more than 15 marketed products in more than 35 indications by 2025-- Aspires to become a leading global biopharmaceutical company

Zai Lab Holds Virtual Research and Development Day

SHANGHAI and SAN FRANCISCO, Sept. 16, 2021 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), an innovative commercial-stage biopharmaceutical company, announced today that it will expand its operations in the U.S. and establish a key presence in the Cambridge biotechnology hub. Business operations to be headquartered in the new Cambridge office include alliance management, business development, legal and governance functions.

Zai Lab Expands U.S. Operations to Join the Cambridge Biotechnology Community

Potential first-in-class therapy for a subset of gastric and gastroesophageal (GEJ) cancers that overexpress fibroblast growth factor receptor 2 (FGFR2b) Potential first-in-class therapy for a subset of gastric and gastroesophageal (GEJ) cancers that overexpress fibroblast growth factor receptor 2 (FGFR2b)

Zai Lab Announces Breakthrough Therapy Designation Granted for Bemarituzumab (FPA144) in China

SHANGHAI and SAN FRANCISCO, Aug. 24, 2021 (GLOBE NEWSWIRE) -- Zai Lab Limited (“Zai Lab”) (NASDAQ: ZLAB; HKEX: 9688), an innovative commercial-stage biopharmaceutical company, today announced that management from Zai Lab will be presenting at the following upcoming virtual investor conferences in September:

Zai Lab Announces Upcoming Presentations in September Investor Conferences

Alibaba

China Fund

Xtrackers MSCI All China Equity ETF

WisdomTree China ex-State-Owned Enterprises Fund

New Oriental Education & Technology Group

First Trust China AlphaDEX Fund

Franklin FTSE China ETF

ProShares UltraShort FTSE China 50

SPDR S&P China ETF

Kraneshares MSCI China Environment Index ETF

Invesco Golden Dragon China ETF

Rayliant Quantamental China Equity ETF

TAL Education Group

Tencent Holdings Limited

Franklin Templeton Dragon Fund

Wuxi Biologics Cayman Inc

ProShares Ultra FTSE China 50

Direxion Daily FTSE China Bear 3X Shares

Direxion Daily FTSE China Bull 3X Shares

ProShares Short FTSE China 50

The rapidly evolving regulatory landscape in China has persistently populated financial market headlines this summer. The cost of raising a larger family can be daunting, particularly as it relates to the “three mountains” of costs associated with childcare – education, healthcare, and housing.

Harnessing Growth: Navigating China's Regulatory Puzzle

Zai Lab Limited (ZLAB) CEO Samantha Du on Q2 2021 Results - Earnings Call Transcript

Company to Host Conference Call and Webcast on August 10, 2021, at 8:00 a.m. EDT Company to Host Conference Call and Webcast on August 10, 2021, at 8:00 a.m. EDT

Zai Lab Announces Second Quarter 2021 Financial Results and Corporate Updates

Stryker

UnitedHealth Group

The Vanguard Health Care Fund (Trades, Portfolio) has revealed its portfolio for the second quarter of this year. Major trades for the fund include a reduction in its portfolio-leading UnitedHealth Group Inc. ( UNH , Financial) position, selling out of its PPD Inc. ( PPD , Financial) and Smith & Nephew PLC ( LSE:SN.

The Vanguard Health Care Fund's Top 5 Trades of the 2nd Quarter

Schrödinger Inc (NASDAQ: SDGR) and Zai Lab Limited (NASDAQ: ZLAB) have collaborated to discover, develop, and commercialize oncology candidate targeting DNA damage response. The research program will be conducted jointly by the Schrödinger and Zai Lab scientific teams.

Schrödinger, Zai Lab Team Up For Cancer Program Targeting DNA Damage Response

Schrodinger 

NEW YORK & SHANGHAI & SAN FRANCISCO--(BUSINESS WIRE)--Schrödinger and Zai Lab today announced a global R&D collaboration in oncology.

Schrödinger and Zai Lab Announce a Global R&D Collaboration in Oncology

As noted in Wall Street Breakfast "Even when you think China risk is priced, it can get worse" Recent Government actions prompt a new degree of caution in further advices; should we go to the point of taking losses now and adjusting score-keeping to reflect committed errors.

Reviewing Our Recent Zai Lab Limited Buy Recommendation

SHANGHAI and SAN FRANCISCO, July 22, 2021 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), an innovative commercial-stage biopharmaceutical company, today announced that it will report financial results and corporate updates for the second quarter ended June 30, 2021 after the closing of the U.S. equity markets on August 9, 2021. The Company will host a live conference call and webcast on August 10, 2021, at 8:00 a.m. EDT.

Zai Lab to Announce Second Quarter 2021 Financial Results

Like it or not, capital gain prospects for stocks in U.S. equities markets are all directly comparable with one another, and investors who want those gains need to make comparisons. The comparability comes from big-money transaction pressures by competing “Institutional” investment organizations adjusting multi-Billion-$ portfolio holdings.

Zai Lab: Best Now Capital Gain Biotech For Near-Term Wealth-Building, So Say Market-Makers

Beam Therapeutics

Bolt Biotherapeutics

Genmab - ADR

MacroGenics

Could new cancer treatment breakthroughs be a bullish sign for small cap stocks?

Hot Small-Cap Stocks To Watch With Potential Cancer Breakthroughs

News for Zai Lab Ltd. Stock (ZLAB)